RBC Analyst Estimates Insmed Takeover Value Between $170 and $210 Per Share Following Sanofi Acquisition Rumors

Insmed (INSM) shares surged 19% following reports that pharmaceutical giant Sanofi (SNY) is considering an acquisition of the drugmaker. The market reaction follows a Bloomberg report suggesting potential takeover interest, which has significantly boosted investor confidence in Insmed's valuation. An analyst from RBC suggests that if a takeover occurs, Insmed could be valued at between $170 and $210 per share. This speculation highlights the growing interest in biotech firms with specialized drug pipelines as larger pharmaceutical companies look to expand their portfolios through strategic acquisitions.

By https://seekingalpha.com/author/sa-editor-joshua-fineman · Seeking Alpha ·

RBC Analyst Estimates Insmed Takeover Value Between $170 and $210 Per Share Following Sanofi Acquisition Rumors

Tickers: $INSM $SNY

Topics: Biotechnology Mergers and Acquisitions Stock Price Movement

Read the full article at Seeking Alpha

More World news